Hyperthyroid Graves’ disease after radioiodine therapy for non-toxic multinodular goiter
Loading...
Date
2008-06-22
Journal Title
Journal ISSN
Volume Title
Publisher
Asian Biomedicine (Research Reviews and News)
Abstract
Background: Radioiodine treatment has been used to reduce the size of euthyroid multinodular goiter (MNG) as an alternative to surgery. Postradioiodine Graves’ disease is a rare side effect which can occur several months after radioiodine treatment for non-toxic multinodular goiter.
Objective: To report two patients who developed hyperthyroid Graves’ disease after radioiodine therapy for non-toxic multinodular goiter.
Methods: We report the clinical and laboratory findings of Graves’ disease which occurred after radiotherapy. The literature was reviewed for the incidence and pathogenesis of Graves’ disease after radioiodine therapy.
Results: The first case describes a 39-year-old woman presented with hyperthyroidism after repeated radioiodine therapy for non-multinodular goiter. The second case describes a 45-year-old woman who presented with hyperthyroidism after the first dose of radioiodine therapy for non-multinodular goiter. Graves’ disease was confirmed in both cases by the presence of thyrotropin receptor antibody (TRAb). Both patients respond well to methimazole.
Conclusion: We demonstrate the rare occurrence of Graves’ disease as the side effect of radioiodine treatment for non-toxic multinodular goiter. They highlight the importance of recognizing patients with hyperthyroidism after radioiodine treatment as they could develop hyperthyroid Graves’ disease following this treatment.
Description
Keywords
Graves’ disease, postradioiodine, non-toxic multinodular goiter
Citation
Asian Biomedicine (Research Reviews and News); Vol. 1 No. 4 December 2007; 407-410.